GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

There is meanwhile a host of other BCMA-targeting drugs angling for a slice of the multiple myeloma market, including GlaxoSmithKline's Blenrep (belantamab mafodotin), an antibody-drug conjugate ...

Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major ...

Armed with new data, GSK is preparing to file for approval of its new-generation meningitis vaccine, as it tries to maintain its leadership in the category against a challenge from Pfizer.